Icosagen Cell Factory Ou

Andres Tover

Ene Ustav

Mart Ustav, Sr

Mart Toots

Mart Ustav

Urve Toots

Toomas Silla

Ingrid Tagen

Tiiu Mandel

Aare Abroi

Jelizaveta Geimanen

Kadri Janikson

Anne Kalling

Radi Tegova

Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.

Human papilloma virus replication inhibitors

A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that expressluciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.

Assay system to identify HPV replication inhibitors in HT-screen

Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.

This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).

Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays

Growing community of inventors

Össu, Estonia

Andres Tover